Legend Biotech Corp - ADR Forecast, price target & analysts
Legend Biotech Corp - ADR Target price 2026 - Analyst rating & recommendation
Legend Biotech Corp - ADR Classifications & Recommendation
Legend Biotech Corp - ADR Price Target
| Target Price | $57.12 |
| Price | $18.62 |
| Potential |
206.77%
register free of charge
|
| Number of Estimates | 18 |
|
18 Analysts have issued a price target Legend Biotech Corp - ADR 2027 .
The average Legend Biotech Corp - ADR target price is $57.12.
This is
206.77%
register free of charge
$77.70
317.29%
register free of charge
$24.24
30.18%
register free of charge
|
|
| A rating was issued by 23 analysts: 17 Analysts recommend Legend Biotech Corp - ADR to buy, 6 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Legend Biotech Corp - ADR stock has an average upside potential 2027 of
206.77%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion $ | 1.03 | 1.47 |
| 64.04% | 42.97% | |
| EBITDA Margin | -10.46% | 4.21% |
| 76.72% | 140.26% |
19 Analysts have issued a sales forecast Legend Biotech Corp - ADR 2026 . The average Legend Biotech Corp - ADR sales estimate is
This results in the following potential growth metrics:
11 Analysts have issued an Legend Biotech Corp - ADR EBITDA forecast 2026. The average Legend Biotech Corp - ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.81 | -0.06 |
| 68.75% | 92.59% | |
| P/E | negative | |
| EV/Sales | 2.05 |
20 Analysts have issued a Legend Biotech Corp - ADR forecast for earnings per share. The average Legend Biotech Corp - ADR EPS is
This results in the following potential growth metrics and future valuations:
Legend Biotech Corp - ADR...
Current Legend Biotech Corp - ADR Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 30 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Sep 11 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 04 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Aug 12 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Aug 12 2026 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Aug 12 2026 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Aug 12 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 30 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Sep 11 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 04 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 12 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Aug 12 2026 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Aug 12 2026 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Aug 12 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
